AstraZeneca has reported positive results from the efzimfotase alfa Phase III clinical trial programme for hypophosphatasia ...
The systemic lupus erythematosus (SLE) market continues to evolve toward biologic-driven care, with increasing treatment complexity, intensifying competition among advanced therapies, and a robust ...
Prior to this, AstraZeneca reported positive results from the efzimfotase alfa Phase III clinical trial programme for ...
UBS and Citi both maintain 'buy' ratings on the Anglo-Swedish drugmaker ahead of its first-quarter results, with a rich ...
Two years ago, the Emerald-1 trial hit its primary endpoint, showing that a cocktail of Imfinzi, Avastin and TACE reduced the ...
April 2 () - AstraZeneca said on Thursday that a combination treatment with its cancer drug Imfinzi showed significant ...
Another phase 3 trial, Chestnut, evaluated children who switched from Strensiq to efzimfotase alfa. The study showed ...
Zacks.com on MSN
Are Medical Stocks Lagging AstraZeneca (AZN) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Astrazeneca (AZN) is a stock that can certainly grab the attention of many investors ...
Extortion: Notorious hackers offering to sell 3GB of data containing highly sensitive intellectual property & infrastructure configuration details.
AstraZeneca Plc AZN released topline data from the Phase 3 program for efzimfotase alfa (ALXN1850) in the broad hypophosphatasia (HPP) patient population. HPP is a rare, inherited metabolic disorder ...
AstraZeneca has delivered a solid trailing 12 months, with shares up 31.43% over the past year, but the stock has pulled back nearly 5% over the past month.
Seven years after the FDA's accelerated approval of bleeding reversal agent Andexxa, which was then under the ownership of Portola Pharmaceuticals, the drug's round trip on the U.S. market is coming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results